iBio, Inc., a biotech innovator and biologics contract development and manufacturing organization (CDMO), has entered into its first Statement of Work (SoW) under a Master Services Agreement with Belgium-based ATB Therapeutics to produce its bioengineered antibody-toxin fusion proteins using iBio’s FastPharming System.   The fusion proteins, called atbodies, are being designed for the treatment of cancers. iBio will develop a manufacturing process and assays for select atbodies per the SoW.   “W...